Image of IncyteCARES logo Image of woman on phone in front of a computer

Connecting eligible patients to support and resources

At IncyteCARES, our mission is to help eligible patients access their prescribed Incyte medication and to offer information and resources that provide extra support during treatment. Our team is available to patients and their caregivers by phone every weekday.

Healthcare Professionals
ENROLL A PATIENT

At IncyteCARES, our mission is to help eligible patients access their prescribed Incyte medication and to offer information and resources that provide extra support during treatment. Our team is available to patients and their caregivers by phone every weekday.

Image that shows Patient Copay/Coinsurance Assistance Card for Jakafi Review additional terms and conditions for copay/coinsurance.* Healthcare Professionals
ENROLL A PATIENT

IncyteCARES MAY HELP ELIGIBLE PATIENTS WITH:

Image of hand for Reimbursement Support

Reimbursement Support

  • Insurance benefit verification
  • Information about prior authorizations
  • Guidance with appealing insurance denials or coverage restrictions
Image of hand for Patient Assistance Options

Patient Assistance Options

  • Copay/coinsurance assistance*
  • Free medication program
  • Temporary access for insurance coverage delays
  • Information about independent nonprofit organizations
Image of book for Education and Support

Education and Support

  • IncyteCARES call center available every weekday
  • Educational information for your patients about their condition and Jakafi
  • Patient Welcome Kit
  • Delivery coordination for Jakafi
Image of building for Help Identifying Support Resources

Help Identifying Support Resources

Information About Independent Organizations That May Be Able To Assist With:

  • Treatment-related transportation or lodging costs
  • Medication cost assistance
  • Emotional and educational support

*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication is required. Please see full criteria for eligibility or call IncyteCARES. Update effective as of September 30, 2019.

Terms, conditions, and additional eligibility criteria apply. Valid prescription for Jakafi for an FDA-approved indication is required. Patients insured through Medicare, Medicaid, and TRICARE are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.

Some organizations may receive donations from Incyte Corporation.

Image of clipboard that says – You may enroll your eligible patients online. IncyteCARES Online Enrollment Form

You may enroll your eligible patients online. IncyteCARES ONLINE
ENROLLMENT FORM

Image of phone that says Connect with IncyteCARES today!

Connect with IncyteCARES today!
Visit IncyteCARES.com or call 1-855-452-5234, Monday through Friday,
8 AM–8 PM ET.

Image of clipboard that says – You may enroll your eligible patients online. IncyteCARES Online Enrollment Form

You may enroll your
eligible patients online.
IncyteCARES
ONLINE ENROLLMENT FORM

Image of phone that says Connect with IncyteCARES today!

Connect with
IncyteCARES today!

Visit IncyteCARES.com or call 1-855-452-5234, Monday through Friday,
8 AM–8 PM ET.

Indications and Usage

Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.

Important Safety Information

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections and edema
  • Dose modifications may be required when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose

Please see Full Prescribing Information for Jakafi.